ASX:BDXPharmaceuticals, Biotechnology & Life SciencesBiotechnology
BCAL Diagnostics Ltd
$0.077
Day Range
$0.071 – $0.080
52 Week Range
$0.052 – $0.155
Volume
0.00
Avg Volume (10D)
1.57M
Market Cap
$28.39M
Price Chart
Market Statistics
Open$0.077
Previous Close$0.077
Day High$0.080
Day Low$0.071
52 Week High$0.155
52 Week Low$0.052
Valuation
Market Cap28.39M
Shares Outstanding368.68M
Price to Book12.23
Trading Activity
Volume0.00
Value Traded0.00
Performance
1 Day-10.75%
5 Day18.57%
13 Week-9.78%
52 Week38.33%
YTD-20.95%
Technical Indicators
RSI (14)50.19
50-Day SMA$0.081
200-Day SMA$0.091
Latest News
Biotechnology
BCAL Diagnostics Develops Blood Test for Breast Cancer Recurrence Monitoring
BCAL Diagnostics launches BREASTEST Monitor—blood test to monitor post-treatment breast cancer recurrence; 91% sensitivity, 95% NPV.
Biotechnology
BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests
BCAL Diagnostics expands access to early cancer blood tests by embedding GP referral forms in major clinical software; launches EarlyDetection telehealth.
Biotechnology
BCAL Diagnostics Accelerates Avantect Rollout via Sonic Healthcare and Healius Partnerships
BCAL Diagnostics speeds Avantect rollout as Sonic Healthcare and Healius expand access to pancreatic/ovarian cancer tests nationwide.
Biotechnology
BCAL Diagnostics on Track for Australian Launch of Aventect Pancreatic and Ovarian Cancer Tests
BCAL Diagnostics (ASX: BDX) is on track to launch the cutting-edge Avantect pancreatic and ovarian cancer tests onto the Australian market in the new year.